HAYWARD, Calif., Feb. 9, 2006 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, announced today that Yoshi Kumagai, President and CEO, will present at the 8th Annual BIO CEO & Investor Conference on Wednesday, Feb. 15, at 2:00 p.m. EST at The Waldorf-Astoria Hotel in New York.
Mr. Kumagai will provide an update on the clinical development of Dentonin(R) (AC-100), a novel small peptide with dental and orthopedic applications. Dentonin(R) is currently being studied in two Phase 2 clinical studies, one in dental restoration procedures and another for the repair of periodontal defects.
About Acologix
Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnering with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (or TRK-820) for the treatment of uremic pruritus in dialysis patients. AC-820 is being studied in a European Phase 3 pivotal clinical trial, with a Phase 3 trial scheduled to launch in the United States in the second half of 2006. For more information go to www.acologix.com.
CONTACT: Yoshi Kumagai, President and CEO of Acologix, +1-510-512-7200, or yoshi.kumagai@acologix.com
Web site: http://www.acologix.com/
